<DOC>
	<DOCNO>NCT01579149</DOCNO>
	<brief_summary>The primary objective ass pharmacokinetics 3 dose level plerixafor injection ( 160 μg/kg , 240 μg/kg , 400 μg/kg ) healthy adult subject Japanese descent . Three cohort subject enrol . Approximately 8 subject enrol cohort , 6 subject receive single subcutaneous ( SC ) dose plerixafor ( 160 μg/kg , 240 μg/kg , 400 μg/kg ) , 2 subject receive single SC dose placebo . The low dose-level cohort ( plerixafor 160 μg/kg ) fully enrol first , follow next high dose-level cohort ( plerixafor 240 μg/kg ) , finally high dose-level cohort ( plerixafor 400 μg/kg ) , provide safety criterion dose escalation meet .</brief_summary>
	<brief_title>A Phase I Dose Escalation Study Plerixafor Healthy Subjects Japanese Descent</brief_title>
	<detailed_description>Screening occur within 28 day prior dose . Dosing occur Day 1 cohort . Subjects remain study center Day -1 discharge approximately 24 hour dose ( Day 2 ) pharmacokinetic , safety , pharmacodynamic assessment ; however , subject receive investigational product , include subject prematurely withdraw study , remain study center minimum 4 hour dose . A 15-day follow-up visit conduct 15 20 day postdose . The study consider complete subject time he/she complete 15-day follow-up visit .</detailed_description>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Healthy male female subject Japanese descent , i.e. , subject born Japan live outside Japan &lt; 10 year , subject 's biological parent grandparent fully Japanese born Japan . Subjects body weight &lt; 95.0 kg male , &lt; 85.0 kg female , &lt; 175 % ideal body weight ( IDW ) The subject estimate creatinine clearance 50 mL/min high determine CockcroftGault formula . The subject 's serum creatinine , alkaline phosphatase , hepatic enzyme ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] ) , total bilirubin ( unless subject document Gilbert syndrome ) exceed upper laboratory normal limit . Other biochemistry , hematology , urinalysis laboratory parameter must exceed National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) Grade 1 . The subject negative HIV , active hepatitis B , active hepatitis C. The subject refrain consume alcohol 48 hour prior Day 1 agrees refrain alcohol consumption discharge center 24 hour prior followup visit ( Day 15 [ +5 day ] ) . Female subject childbearing potential male subject partner childbearing potential agree use effective mean birth control study therapy minimum 1 month follow final study visit . Effective birth control include : ( ) birth control pill , depot progesterone , intrauterine device plus one barrier method ; ( b ) 2 barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm ) . For subject use hormonal contraceptive method , information interaction plerixafor hormonal contraceptive know . The subject give write informed consent prior undertake studyrelated procedure . History clinically significant cardiac disorder , pulmonary disorder , malignancy , major medical issue , view Investigator , render subject high risk treatment complication . Known allergy sensitivity plerixafor . Blood donation within 30 day prior Day 1 . Active infection , include unexplained fever ( temperature &gt; 38.1ºC ) antibiotic and/or antiviral therapy within 7 day prior Day 1 . Abnormal electrocardiogram ( ECG ) clinically significant conduction ( heart block ; QTc &gt; 430 m [ male ] QTc &gt; 450 m [ female ] ) rhythm disturbance ( ventricular arrhythmia ) within 1 year prior Day 1 , opinion Investigator , warrant exclusion subject study . History known current alcohol , narcotic , illicit drug abuse within past 5 year . If female , pregnant ( defined positive serum βHCG test ) lactating . Any medication , include overthecounter medication and/or alternative medication ( eg , dietary , herbal , botanical , homeopathic supplement ) , within 7 day prior Day 1 , exception hormonal birth control . Blood transfusion 30 day prior Day 1 . The subject tolerate venipuncture . In opinion Investigator , subject unable adhere requirement study . The subject previously receive investigational therapy within 4 week Day 1 within 6 week Day 1 case longacting agent ( halflife &gt; 14 day ) antibody , currently enrol another investigational protocol , plan receive investigational product time course study time final followup visit .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>